The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women

Clinical Endocrinology

Volumn 51, Issue 5, 1999, Pages 643-651

  Schlegel, W ^a,e   Petersdorf, L I ^a   Junker, R ^b,c   Schulte, H ^c   Ebert, C ^d   Von Eckardstein, A ^b,c,e  

^a Dept of Obstet and Gynaecology ^*  (Germany)

^b Inst of Clin Chem and Lab Med   (Germany)

^c Institute of Pathology   (Germany)

^d Solvay Pharmaceuticals GmbH   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; FIBRINOGEN; FOLLITROPIN; LIPOPROTEIN A; MEDROGESTONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRASTERONE SULFATE; PROCOLLAGEN; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BONE TURNOVER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HEMOSTASIS; HUMAN; LIPID METABOLISM; MENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032706989     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1999.00857.x     Document Type: Article

References (55)

1. Agnusdei, D., Gennari, C. & Bufalino, L. (1995) Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug iprillavone. Osteoporosis International, 5, 462-466.
2. Barrett-Connor, E., Slone, S., Greendale, G., Kritz-Silverstein, D., Espeland, M., Johnson, S.R., Waclawiw, M. & Fineberg, S.E. (1997) The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas, 27, 261-274.
3. Barrett-Connor, E. & Khaw, K.T. (1987) Absence of an inverse relation of dehydroepiandrosteroneysulfate with cardiovascular mortality in postmenopausal women. New England Journal of Medicine, 317, 711.
4. Barzel, U.S. (1988) Estrogens in Ihe prevention and treatment of post-menopausal osteoporosis. American Journal of Medicine, 85, 847-850.
5. Belchetz, P.E. (1994) Hormonal treatment of postmenopausal women. New England Journal of Medicine, 330, 1062-1071.
6. Berg, G., Halperin, H., Vilarino, A., Lopez, G., Contreras Ortiz, O., Tempone, A. & Wikinski, R. (1997) Plasma apolipoproteins and lipid composition of lipoproteins in pre-and postmenopausal women. European Menopause Journal, 4, 4-13.
7. Bush, T.L. (1996) Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. European Heart Journal, 17 (Suppl.), 9-14.
8. Castelo-Branco, C., Martinez de Osaba, M.J., Pons, F. & Gonzáles-Merlo, J. (1992) The effect of hormone replacement therapy on postmenopausal bone loss. European Journal of Obstetrics and Gynecology and Reproductive Biology, 44, 131-136.
9. Christiansen, C. & Lindsay, R. (1990) Estrogens, bone loss and preservation. Osteoporosis International, 1, 7-13.
10. Colditz, G.A., Hankinson, S.E., Hunter, D.J., Willett, W.C., Manson, J.E., Stampfer, M.J., Hennekens, C., Roner, B. & Speizer, F.E. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal of Medicine, 332, 1589-1593.
11. Collins, P., Rosano, G.M.C., Sarrel, P.M., Ulrich, L., Adamopoulos, S., Beale, C.M., McNeill, J.G. & Poole-Wilson, P.A. (1995) Betaestradiol attenuates acetylcholin-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation, 92, 24-30.
12. Consensus Development Conference (1987) Prophylaxis and treatment of osteoporosis. British Medical Journal, 295, 914-915.
13. Cunningham, S.K., Loughlin, T., Culliton, M. & McKenna, T.J. (1983) Plasma sex hormone-binding globuline and androgen levels in the management of hirsute patients. Acta Endocrinologica, 104, 365-371.
14. Davie, M.W.J., Evans, S.F. & Haddaway, M.J. (1994) Low dose HRT prevents bone loss at ages up to 75 years. Bone, 15, 730. (Abstract).
15. De Lignières, B. (1996) Estrogen replacement therapy must be customized. European Menopausal Journal, 3, 21-25.
16. Delmas, P. & Gimona, A. (1996) Osteoporosis prevention clinical study program. European Journal of Obstetrics & Gynecology and Reproductive Biology, 64 (Suppl.), S39-45.
17. Espeland, M.A., Marcovina, S.M., Miller, V., Wood, P.D., Wasilauskas, C., Sherwin, R., Schrott, H. & Bush, T.L. (1998) Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. PEPI investigators. Postmenopausal estrogen/progestin interventions. Circulation, 97, 979-986.
18. Ettinger, B., Gennant, H.K. & Cann, C.E. (1987) Long-term estrogen replacement therapy prevents bone loss and fractures. Annual Internal Medicine, 102, 319-324.
19. Ettinger, B., Gennant, H.K. & Cann, C.E. (1987) Post-menopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Annual Internal Medicine, 106, 40-45.
20. Evans, S.F. & Davie, M.W.J. (1996) Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clinical Endocrinology, 44, 79-84.
21. Farish, E., Rolton, H.A., Barnes, J.F., Fletcher, C.D., Walsh, D.J., Spowart, K.J.M. & Hart, D.M. (1993) Lipoprotein (a) and postmenopausal oestrogen. Acta Endocrinologica, 129, 225-228.
22. Friedewald, W.T., Levy, R. & Fredrickson, D.S. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499-502.
23. Grady, D., Rubin, S.N., Petitti, D.B., Fox, C.S., Black, D., Ettinger, B., Ernster, V.L. & Cummings, S.R. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Annual Internal Medicine, 117, 1016-1037.
24. Grodstein, F., Stampfer, M.J., Manson, J.E., Colditz, G.A., Willett, W.C., Rosner, B., Speizer, F.E. & Henneken, C.H. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine, 335, 453-461.
25. Hänggi, W., Lippuner, K., Riesen, W., Jaeger, P. & Birkhäuser, M.H. (1997) Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study. British Journal of Obstetrics and Gynaecology, 104, 700-717.
26. Hassager, C., Risteli, J., Risteli, L. & Christiansen, C. (1994) Effect of the menopause and hormone replacement therapy on the carboxyterminal pyridinoline cross-linked telopeptide of type I collagen. Osteoporosis International, 4, 349-352.
27. Hillard, T.C., Whiteroft, S.J., Marsh, M.S., Ellerington, M.C., Lees, B., Whitehead, M.I. & Stevenson, J.C. (1994) Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis International, 4, 341-348.
28. Hirvonen, E., Elliesen, J. & Schmidt-Gollwitzer, K. (1990) Comparison of two hormone replacement regimens. Influence on lipoproteins and bone mineral content. Maturitas, 12, 127-136.
29. Hokanson, J.E. & Austin, M.A. (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk, 3, 213-219.
30. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. & Vittinghoff, E. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. The Journal of the American Medical Association, 280, 605-613.
31. International Task Force for the Prevention of Coronary Heart Disease (1998) Coronary heart disease. Reducing the risk. Nutrition, Metabolism and Cardiovascular Diseases, 8, 205-271.
32. Jick, H., Derby, L.E., Wald Meyers, M., Vasilakis, C. & Newton, K.M. (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet, 348, 981-983.
33. Junker, R., Heinrich, J., Schulte, H., van deLoo, J. & Assmann, G. (1997) Coagulation factor VII and the risk of coronary heart disease in healthy men. Arteriosclerosis, Thrombosis and Vascular Biology, 17, 1539-1544.
34. Kanis, J.A. (1995) Treatment of osteoporosis in elderly women. American Journal of Medicine, 98, 605-665.
35. Kaufman, J.M. (1997) Pharmacokinetics of oestrogens and hormone replacement therapy. European Menopause Journal, 4, 14-22.
36. Kauppila, A., Risteli, J. & Gennari, C. (1996) Postmenopausal osteoporosis. European Menopause Journal, 3, 219-226.
37. Lamberts, S.W.J., van den Beld, A.W. & van der Lely, A.J. (1997) The endocrinology of aging. Science, 278, 419-424.
38. Lobo, R. (1992) Estrogen and the risk of coagulopathy. American Journal of Medicine, 92, 275-282.
39. McCrohon, J.A., Adams, M.R., McCredie, R.J., Robinson, J., Pike, A., Abbey, M., Keech, A.C. & Celermajer, D.S. (1996) Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clinical Endocrinology. 45, 435-441.
40. Meade, T.W., Ruddock, V., Stirling, Y., Chakrabarti, R. & Miller, G.J. (1993) Fibrinolytic-activily, clotting factors, and long term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet, 342, 1076-1079.
41. Metka, M., Holzer, G., Raiman, H., Heytmanck, G. & Kurz, C. (1994) The role of prolactin in the menopause. Maturitas, 20, 151-154.
42. Nabulsi, A.A., Folsom, A.R., White, A., Patsch, W., Heiss, G., Wu, K.K. & Szklo, M. (1993) Association of hormone replacement therapy with various cardiovascular risk factors in post-menopausal women. New England Journal of Medicine, 328, 1069-1075.
43. Reyes, F.I., Winter, J.S.D. & Faiman, C. (1977) Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. American Journal of Obstetrics and Glynecology, 129, 557-564.
44. Risteli, J., Elomaa, I., Niemi, S., Novamo, A. & Risteli, L. (1993) Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clinical Chemistry, 39, 635-640.
45. Sarrel, P.M. (1995) How progestins compromise the cardioprotective effects of etrogens. Menopause, 2, 187-190.
46. Schlegel, W., Müller, H., Ebert, C., Dame, W. & Schneider, H.P.G. (1994) Östrogensubstitution: Effecte auf den Lipid-, Eicosanoid-und Collagenstoffwechsel in der Menopause. Zentralblatt für Gynäkologie, 116, 179-184.
47. Sonnendecker, E.W.W., Polakow, E.S., Spinnler Benadé, A.J. & Simchowitz, E. (1989) Serum lipoprotein effects of conjugated estrogens and a sequential conjugated estrogen-medrogestone regimen in hysterectomized postmenopausal women. American Journal of Obstetrics and Gynecology, 160, 1128-1134.
48. Stampfer, M.J. & Colditz, G.A. (1991) Estrogen replacement therapy on coronary heart disease: quantitative assessment of the epidemiologic evidence. Preventive Medicine, 273, 47-63.
49. Teichmann, A.T., Wieland, H., Cremer, P., Hinney, B., Kuhn, W. & Seidel, D. (1985) Effects of medrogestone and conjugated oestrogens on serum lipid and lipoprotein concentrations. Maturitas, 7, 343-350.
50. The Writing Group for the PEPI (1995) Effects of estrogens or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI trial. The Journal of the American Medical Association, 273, 199-208.
51. The Writing Group for the, PEPI (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/ progestin interventions (PEPI) trial. The Writing Group for the PEPI. The Journal of the American Medical Association, 276, 1389-1396.
52. von Eckardstein, A. & Assmann, G. (1998) High density lipoproteins and reverse cholesterol transport: Lessons from mutations. Atherosclerosis, 137 (Suppl.), S7-S11.
53. von Eckardstein, A., Huang, Y. & Assmann, G. (1994) Physiological role and clinical relevance of high density lipoprotein subclasses. Current Opinions in Lipidology, 5, 404-416.
54. Winkler, U.H. (1993) Menopause, hormone replacement therapy and cardiovascular disease: a review of haemostaseolocical findings. Fibrinolysis, 6 (Suppl.), 5-10.
55. Ylöstalo, P., Kauppila, A., Kivinen, S., Tuimala, S. & Vihko, R. (1983) Endocrine and metabolic effects of low-dose estrogen progestin treatment in climacteric women. Obstetrics and Gynecology, 62, 682-686.